Alzor HCT Adverse Reactions

The most commonly reported adverse reactions during treatment with Olmesartan and Hydrochlorothiazide are headache (2.9%), dizziness (1.9%) and fatigue (1.0%).
Hydrochlorothiazide may cause or exacerbate volume depletion which may lead to electrolyte imbalance.
Adverse reactions from Olmesartan and Hydrochlorothiazide in clinical trials, post-authorisation safety studies and spontaneous reporting are summarised in the tables as follows as well as adverse reactions from the individual components Olmesartan Medoxomil and hydrochlorothiazide based on the known safety profile of these substances.
The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data). (See Tables a and b.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image

Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers.